{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:47:13Z","timestamp":1793083633342,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65267-0","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:02:48Z","timestamp":1763978568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed\/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Hubert","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Cranert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S.","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bacong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff D.","family":"Eskew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"McCaigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly","family":"Krasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Solimine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Loyola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3263-2374","authenticated-orcid":false,"given":"Andrew","family":"Kin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin L.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet H.","family":"Kocoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Namini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Belani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Coronella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-7510","authenticated-orcid":false,"given":"Devon J.","family":"Shedlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"65267_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"65267_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med"},{"key":"65267_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med"},{"key":"65267_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med 29, 422\u2013429 (2023).","journal-title":"Nat. Med"},{"key":"65267_CR5","doi-asserted-by":"crossref","unstructured":"Bailur, J. K. et al. Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 5, e127807(2019).","DOI":"10.1172\/jci.insight.127807"},{"key":"65267_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 9, 116 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"65267_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.omtn.2022.06.003","volume":"29","author":"BB Madison","year":"2022","unstructured":"Madison, B. B. et al. Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of T(SCM)-enriched allogeneic CAR-T cells. Mol. Ther. Nucleic Acids 29, 979\u2013995 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"65267_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemi. Nat. Med 24, 563\u2013571 (2018).","journal-title":"Nat. Med"},{"key":"65267_CR9","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med 26, 1878\u20131887 (2020).","journal-title":"Nat. Med"},{"key":"65267_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat. Med 30, 507\u2013518 (2024).","journal-title":"Nat. Med"},{"key":"65267_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","volume":"5","author":"S Filosto","year":"2024","unstructured":"Filosto, S. et al. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). Blood Cancer Discov. 5, 21\u201333 (2024).","journal-title":"Blood Cancer Discov."},{"key":"65267_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","volume":"2","author":"L Biasco","year":"2021","unstructured":"Biasco, L. et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat. Cancer 2, 629\u2013642 (2021).","journal-title":"Nat. Cancer"},{"key":"65267_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"65267_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12, 749\u2013761 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"65267_CR15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670\u2013684 (2007).","journal-title":"Immunity"},{"key":"65267_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm.2232","volume":"16","author":"M Quigley","year":"2010","unstructured":"Quigley, M. et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med 16, 1147\u20131151 (2010).","journal-title":"Nat. Med"},{"key":"65267_CR17","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1073\/pnas.0511137103","volume":"103","author":"CJ Luckey","year":"2006","unstructured":"Luckey, C. J. et al. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc. Natl Acad. Sci. USA 103, 3304\u20133309 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"65267_CR18","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med 17, 1290\u20131297 (2011).","journal-title":"Nat. Med"},{"key":"65267_CR19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","volume":"132","author":"J Rossi","year":"2018","unstructured":"Rossi, J. et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood 132, 804\u2013814 (2018).","journal-title":"Blood"},{"key":"65267_CR20","doi-asserted-by":"crossref","unstructured":"Lamure, S., et al. Clinical and product features associated with outcome of DLBCL patients to CD19-targeted CAR T-cell therapy. Cancers (Basel) 13, 4279 (2021).","DOI":"10.3390\/cancers13174279"},{"key":"65267_CR21","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney, O. C. et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J. Clin. Invest 129, 2123\u20132132 (2019).","journal-title":"J. Clin. Invest"},{"key":"65267_CR22","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","volume":"125","author":"A Roberto","year":"2015","unstructured":"Roberto, A. et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood 125, 2855\u20132864 (2015).","journal-title":"Blood"},{"key":"65267_CR23","doi-asserted-by":"crossref","unstructured":"Battram, A. M. et al. IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15\/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers (Basel) 13(2021).","DOI":"10.3390\/cancers13143534"},{"key":"65267_CR24","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"65267_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"65267_CR26","doi-asserted-by":"publisher","first-page":"eabj2820","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","journal-title":"Sci. Adv."},{"key":"65267_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med"},{"key":"65267_CR28","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1182\/blood-2021-151672","volume":"138","author":"C Costello","year":"2021","unstructured":"Costello, C. et al. Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System. Blood 138, 3858\u20133858 (2021).","journal-title":"Blood"},{"key":"65267_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"65267_CR30","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med 8, 355ra116 (2016).","journal-title":"Sci. Transl. Med"},{"key":"65267_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/2767-9764.CRC-21-0157","volume":"2","author":"AM Metelo","year":"2022","unstructured":"Metelo, A. M. et al. Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. Cancer Res Commun. 2, 158\u2013171 (2022).","journal-title":"Cancer Res Commun."},{"key":"65267_CR32","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","volume":"27","author":"C Sommer","year":"2019","unstructured":"Sommer, C. et al. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Mol. Ther. 27, 1126\u20131138 (2019).","journal-title":"Mol. Ther."},{"key":"65267_CR33","unstructured":"Harrell, F. E. Jr. Hmisc. Harrell Miscellaneous"},{"key":"65267_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"65267_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"65267_CR36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888\u20131902 e1821 (2019).","journal-title":"Cell"},{"key":"65267_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"65267_CR38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"65267_CR39","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo, M. et al. Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 18, e206\u2013e217 (2017).","journal-title":"Lancet Oncol."},{"key":"65267_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ajh.21913","volume":"86","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 86, 57\u201365 (2011).","journal-title":"Am. J. Hematol."},{"key":"65267_CR41","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31, 2443\u20132448 (2017).","journal-title":"Leukemia"},{"key":"65267_CR42","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: elegant graphics for data analysis. in Use R! (Springer International Publishing, Cham, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"65267_CR43","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino, M. et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a european myeloma network (EMN) report within the HARMONY project. J. Clin. Oncol. 40, 3406\u20133418 (2022).","journal-title":"J. Clin. Oncol."},{"key":"65267_CR44","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65267-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65267-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65267-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:02:50Z","timestamp":1763978570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65267-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65267"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65267-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.T., S.A.C., M.R.,\u00a0K.S.M., B.S.C., A.B., K.M.,\u00a0J.D.E., J.M., S.H., A.Kr., B.S., M.J.C., A.L., J.K., H.N., C.E.M., R.B., J.C., and D.J.S. were employees of Poseida Therapeutics\u00a0during their\u00a0contribution to this study. B.D. has received research funding from Janssen Pharmaceuticals, Angiocrine Bioscience, Pfizer, Poseida Therapeutics, MEI Pharma, Orca Bio, Wugen, AlloVir, Adicet Bio, Bristol Myers-Squibb (BMS), Molecular Templates, Atara Biotherapeutics, and the National Cancer Institute (NCI), and has consulted for MJH Life Sciences, Arivan Research, Janssen Pharmaceuticals, ADC Therapeutics, Gilead Sciences, GlaxoSmithKline, Caribou Biosciences, Roche, and Autolous Therapeutics. C.L.C. has received research funding from BMS, Takeda Pharmaceuticals, and Janssen Pharmaceuticals, and has consulted for BMS, Janssen Pharmaceuticals, Genentech, Karyopharm Therapeutics, Pfizer, and Kite Pharma. L.S. holds advisory board roles with Novartis, Johnson and Johnson, and BMS. A.R. has received research support from Novartis, Pfizer, and AstraZeneca. M.H.K. and A.Ki. have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10050"}}